Galmed Pharmaceuticals Ltd. SEC filings EOCN
Galmed Pharmaceuticals Ltd. has 381 filings in SEC EDGAR's recent list, going back to Dec 31, 2013. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 9, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 7, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 18, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Sep 20, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Sep 20, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Jul 21, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 7, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 27, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 16, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 15, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Jul 28, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jun 22, 2018 | — |
| SC 13G | Ownership over 5% (passive) | Apr 16, 2018 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 26, 2018 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 26, 2018 | — |
| SC 13G | Ownership over 5% (passive) | Dec 18, 2017 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2017 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2017 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 16, 2016 | — |
| SC 13G | Ownership over 5% (passive) | Jan 13, 2015 | — |
| SC 13G | Ownership over 5% (passive) | Jan 13, 2015 | — |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EOCN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1595353
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.